Breaking News

Baxter Divests BioPharma Solutions Biz to Advent, Warburg Pincus for $4.25B

Transaction includes BPS manufacturing facilities and approximately 1,700 employees in Bloomington, IN and Halle, Germany.

Baxter International Inc., a global medtech company, signed a definitive agreement to divest its BioPharma Solutions (BPS) business to Advent International, a global private equity investor, and Warburg Pincus, a global growth investor. Under the agreement, Baxter will receive $4.25 billion in cash, subject to certain closing adjustments, with net after-tax proceeds currently estimated to be approximately $3.4 billion. The transaction is expected to close in the second half of 2023. Baxter...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters